A Phase 3 trial (NCT07529977) evaluating oral minoxidil (N1087) vs placebo in men with AGA was posted to ClinicalTrials.gov in April 2026. Separately, a 2026 patient survey found unwanted hair growth (hypertrichosis) in 71.6% of women on LDOM.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
In use (off-label)
How it works
Oral vasodilator (repurposed blood-pressure drug) taken at low doses to stimulate hair growth, thought to work via vasodilation and prolonging the anagen phase.
Results so far
Reported adverse-effect rates: dose-dependent hypertrichosis ~24%, transient shedding 16-22%, mild peripheral edema ~2%; serious complications (e.g., pericardial effusion) rare at alopecia doses. International Delphi consensus dosing: 1.25 mg/day starting dose for women, 2.5 mg/day for men.
What's next
No approval pathway exists yet for a branded low-dose oral minoxidil product for hair loss; use remains off-label pending outcome of trials like N1087.
In India
No India-specific trial identified; oral minoxidil is already widely prescribed off-label in India as elsewhere, but this was not independently confirmed with an Indian source.
Sources
- Trial registry ↗ (accessed 2026-10-17)
- Journal paper ↗ (accessed 2026-10-17)
- Journal paper ↗ (accessed 2026-10-17)
- Journal paper ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil and, for men, finasteride.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.